Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials

被引：0
|
作者：
Xin-Lin Zhang
Qing-Qing Zhu
Li Zhu
Jian-Zhou Chen
Qin-Hua Chen
Guan-Nan Li
Jun Xie
Li-Na Kang
Biao Xu
机构：
[1] Nanjing University School of Medicine,Department of Cardiology, Affiliated Drum Tower Hospital
[2] Jinling Hospital,Department of Respiratory Medicine
[3] Nanjing University School of Medicine,Department of Radiology, Affiliated Drum Tower Hospital
[4] Nanjing University School of Medicine,undefined
来源：
BMC Medicine | / 13卷
关键词：
PCSK9; Monoclonal antibody; Evolocumab; Alirocumab; Safety; Efficacy; LDL-C; Meta-analysis; Randomized controlled trials;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials
    Zhang, Xin-Lin
    Zhu, Qing-Qing
    Zhu, Li
    Chen, Jian-Zhou
    Chen, Qin-Hua
    Li, Guan-Nan
    Xie, Jun
    Kang, Li-Na
    Xu, Biao
    BMC MEDICINE, 2015, 13
  • [2] SAFETY AND CARDIOVASCULAR EFFICACY OF ANTI-PCSK9 MONOCLONAL ANTIBODIES: A META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS
    Casula, M.
    Olmastroni, E.
    Taddeo, M. Boccalari
    Tragni, E.
    Pirillo, A.
    Luigi, A. Catapano
    ATHEROSCLEROSIS, 2019, 287 : E39 - E39
  • [3] LDL cholesterol decrease by anti-PCSK9 monoclonal antibodies: Systematic review, meta-analysis and meta-regression of randomized controlled trials
    Ma, I.
    Angoulvant, D.
    Azzopardi, N.
    Ternant, D.
    Ivanes, F.
    Paintaud, G.
    Angoulvant, T. Bejan
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2021, 35 : 21 - 22
  • [4] LDL-cholesterol decrease by anti-PCSK9 monoclonal antibodies: systematic review, meta-analysis and meta-regression of randomized controlled trials
    Ma, I
    Angoulvant, D.
    Azzopardi, N.
    Ternant, D.
    Ivanes, F.
    Paintaud, G.
    Bejan-Angoulvant, T.
    EUROPEAN HEART JOURNAL, 2020, 41 : 3334 - 3334
  • [5] The efficacy of anti-PCSK9 antibodies: Results from recent trials
    Gouni-Berthold, Ioanna
    ATHEROSCLEROSIS SUPPLEMENTS, 2017, 30 : 9 - 18
  • [6] Update of Clinical Trials of Anti-PCSK9 Antibodies
    Na-Qiong Wu
    Sha Li
    Jian-Jun Li
    Cardiovascular Drugs and Therapy, 2015, 29 : 159 - 169
  • [7] Update of Clinical Trials of Anti-PCSK9 Antibodies
    Wu, Na-Qiong
    Li, Sha
    Li, Jian-Jun
    CARDIOVASCULAR DRUGS AND THERAPY, 2015, 29 (02) : 159 - 169
  • [8] Efficacy and safety of PCSK9 inhibition in cardiovascular disease: A meta-analysis of 45 randomized controlled trials
    Geng, Qiang
    Li, Xuan
    Sun, Qingjiao
    Wang, Zhengzhong
    CARDIOLOGY JOURNAL, 2022, 29 (04) : 574 - 581
  • [9] Efficacy and Safety of PCSK9 Monoclonal Antibodies in Patients at High Cardiovascular Risk: An Updated Systematic Review and Meta-Analysis of 32 Randomized Controlled Trials
    Guangyan Mu
    Qian Xiang
    Shuang Zhou
    Zhiyan Liu
    Litong Qi
    Jie Jiang
    Yanjun Gong
    Qiufen Xie
    Zining Wang
    Hanxu Zhang
    Yong Huo
    Yimin Cui
    Advances in Therapy, 2020, 37 : 1496 - 1521
  • [10] Efficacy and Safety of PCSK9 Monoclonal Antibodies in Patients at High Cardiovascular Risk: An Updated Systematic Review and Meta-Analysis of 32 Randomized Controlled Trials
    Mu, Guangyan
    Xiang, Qian
    Zhou, Shuang
    Liu, Zhiyan
    Qi, Litong
    Jiang, Jie
    Gong, Yanjun
    Xie, Qiufen
    Wang, Zining
    Zhang, Hanxu
    Huo, Yong
    Cui, Yimin
    ADVANCES IN THERAPY, 2020, 37 (04) : 1496 - 1521
12345